Expertise in
12
conditions

Dr. Anne C. Chiang

Oncology
Yale University
20 York St, 
New Haven, CT 
Offers Telehealth
Expertise in
12
conditions
Yale University
20 York St, 
New Haven, CT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Anne Chiang is an Oncologist in New Haven, Connecticut. Dr. Chiang is highly rated in 12 conditions, according to our data. Her top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Squamous Cell Lung Carcinoma.

Her clinical research consists of co-authoring 54 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in CT
Hospital Affiliations
Yale-New Haven Hospital
Bridgeport Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

YALE UNIVERSITY
20 York St, New Haven, CT 06510
Other Locations
YALE UNIVERSITY
6 Devine St, North Haven, CT 06473
YALE UNIVERSITY
800 Howard Ave, New Haven, CT 06519

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Study Phase: Phase 3
A Pilot Study of Combination Immunotherapy With Ipilimumab and Nivolumab in Patients With Recurrent Extensive Stage Small Cell Lung Cancer (SCLC) Who Have Previously Received Platinum-based Chemotherapy
A Pilot Study of Combination Immunotherapy With Ipilimumab and Nivolumab in Patients With Recurrent Extensive Stage Small Cell Lung Cancer (SCLC) Who Have Previously Received Platinum-based Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: July 20, 2025
Intervention Type: Drug
Study Drug: Ipilimumab+Nivolumab
Study Phase: Phase 2
A Window Study to Assess the Activity of Demethylation Therapy in Patients With HPV-Positive Compared With HPV-Negative Head and Neck Squamous Cell Carcinoma, With Response Assessment and Biomarker Expansion Cohort in HPV-Positive Oropharynx Cancer
A Window Study to Assess the Activity of Demethylation Therapy in Patients With HPV-Positive Compared With HPV-Negative Head and Neck Squamous Cell Carcinoma, With Response Assessment and Biomarker Expansion Cohort in HPV-Positive Oropharynx Cancer
Enrollment Status: Completed
Publish Date: February 15, 2022
Intervention Type: Drug
Study Drug: 5-Azacitadine
Study Phase: Phase 1
An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)
An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)
Enrollment Status: Completed
Publish Date: July 30, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Study of MK-3475 in Patients With Metastatic Melanoma and Non-Small Cell Lung Cancer With Untreated Brain Metastases
A Phase 2 Study of MK-3475 in Patients With Metastatic Melanoma and Non-Small Cell Lung Cancer With Untreated Brain Metastases
Enrollment Status: Completed
Publish Date: March 24, 2021
Intervention Type: Drug
Study Phase: Phase 2
A 2-Arm Phase 2 Double-Blind Randomized Study of Carboplatin, Pemetrexed Plus Placebo Versus Carboplatin, Pemetrexed Plus Truncated Demcizumab as First-Line Treatment in Subjects With Stage IV Non-Squamous Non-Small Cell Lung Cancer
A 2-Arm Phase 2 Double-Blind Randomized Study of Carboplatin, Pemetrexed Plus Placebo Versus Carboplatin, Pemetrexed Plus Truncated Demcizumab as First-Line Treatment in Subjects With Stage IV Non-Squamous Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: September 09, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Study of LY2606368 in Patients With Extensive Stage Disease Small Cell Lung Cancer
A Phase 2 Study of LY2606368 in Patients With Extensive Stage Disease Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: March 17, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

54 Total Publications

Small-Cell Lung Cancer Updates.
Small-Cell Lung Cancer Updates.
Journal: Seminars in respiratory and critical care medicine
Published: August 07, 2025
Similar Doctors
Expertise in
16
conditions
Dr. Scott N. Gettinger
Oncology | Hematology
Expertise in
16
conditions
Dr. Scott N. Gettinger
Oncology | Hematology

Yale University

35 Park St, 
New Haven, CT 
 (0.1 miles away)
203-785-4191
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Scott Gettinger is an Oncologist and a Hematologist in New Haven, Connecticut. Dr. Gettinger is highly rated in 16 conditions, according to our data. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Gamma Knife Radiosurgery.

Francine M. Foss
Expertise in
21
conditions
Dr. Francine M. Foss
Oncology
Expertise in
21
conditions
Dr. Francine M. Foss
Oncology

Yale University

20 York St, 
New Haven, CT 
 (0.1 miles away)
203-688-2433
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Francine Foss is an Oncologist in New Haven, Connecticut. Dr. Foss is highly rated in 21 conditions, according to our data. Her top areas of expertise are Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), and Non-Hodgkin Lymphoma.

Eric P. Winer
Expertise in
11
conditions
Dr. Eric P. Winer
Oncology | Hematology Oncology
Expertise in
11
conditions
Dr. Eric P. Winer
Oncology | Hematology Oncology

Yale University

35 Park St, 
New Haven, CT 
 (0.1 miles away)
203-785-4191
Languages Spoken:
English
See accepted insurances

Eric Winer is an Oncologist and a Hematologist Oncology provider in New Haven, Connecticut. Dr. Winer is highly rated in 11 conditions, according to our data. His top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, HER-2 Positive Breast Cancer, and Breast Cancer in Men.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chiang's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile